Mounjaro Injection
US$ 24.30
glp-1 agonists for type 2 diabetes New Developments in Pharmacological Treatment of Obesity and Diabetes—Beyond and within Receptor Comparing Ozempic, Wegovy and Other
Description
For additional information on obesity rates and racial disparities, see KFFs policy watch: What are the Implications of New Anti-Obesity Drugs for Racial Disparities
Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period
When designed well, these policies can expand equitable access, give providers the tools they need to implement secure telehealth solutions, and remove regulatory barriers that slow adoption
Milky G, Thomas J 3rd
